Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)

Launched by ERASME UNIVERSITY HOSPITAL · Apr 20, 2023

Keywords

ClinConnect Summary

The SENSE-II/AROUSE trial is a research study focused on understanding a serious condition called Status Epilepticus (SE), where a person has prolonged or repeated seizures without regaining consciousness in between. This study aims to gather information about patients with SE, including their symptoms, the treatments they receive, and the outcomes of their care. By collecting this data from various hospitals, researchers hope to identify factors that can help predict how well patients will respond to treatment.

To participate in this trial, individuals must be 18 years or older and either be admitted primarily for Status Epilepticus or be diagnosed with it during their hospital stay for another reason. However, those who have SE due to a heart-related issue after a cardiac arrest are not eligible. Participants will help researchers learn more about this condition and how to improve care for future patients. If you or someone you know is facing this situation, joining the study could contribute to valuable insights in treating SE.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or above
• • Patients admitted for management of Status Epilepticus as their primary diagnosis
• • Patients admitted for another primary diagnosis but identified with Status Epilepticus during their acute hospital stay
• Exclusion Criteria:
• • - Patients with post-cardiac arrest SE